From the Ground Up: Evolving Strategies in the Identification and Team-based Management of Patients with Early-Stage Alzheimer’s Disease Neurobiology

Program Description

The care of Alzheimer’s disease (AD) is involved, multifaceted, and variable depending on individual patient preferences. With the introduction of novel tools and strategies for diagnosis and therapy, additional clinicians and responsibilities are being introduced into AD management each day. Though these developments are highly promising for patients, their integration is complicated by the wide breadth of providers in disparate practice locations/specialties that can be responsible for them. Without clarity on which elements fall under the umbrella of each provider or corresponding proficiency in the fulfillment of these elements, clinicians may fail to effectively implement key components of care, allowing patients to fall through the cracks.

To help correct for such oversights and ensure comprehensive care, the proposed activity series is designed to help delineate and address the different modern roles in the current management of AD across clinical specialties. By exploring individual roles and their effective execution, providers involved in AD can more confidently and proficiently ensure that their patients are receiving complete and optimal care.

Target Audience

This activity is intended for general practice and internal medicine physicians, neurologists, geriatricians, radiologists, psychiatrists, advanced practice professionals, registered nurses, and pharmacists involved in the diagnosis and management of Alzheimer’s disease.

Learning Objectives

Part 1: Suspicion, Identification, and Evaluation of Patients Who May Have Early Alzheimer's Disease Neurobiology

  • Recognize subtle clinical indicators of early cognitive impairment and their distinction from age-related cognitive decline to more effectively identify appropriate candidates for formal cognitive testing
  • Appraise the utility of available clinical assessment scales in evaluating mild cognitive impairment (MCI) and the implications of their results to ensure patients are optimally evaluated and started on the best care path

Part 2: Importance and Implications of Biomarkers in Diagnosis and Modern Treatment of Alzheimer's Disease

  • Define the clinical uses of AD biomarker analyses (e.g., CSF, PET, serum), including both their diagnostic and therapeutic implications, to better streamline and individualize patient management
  • Evaluate patient selection for and phase 3 data with new and emerging amyloid-targeting therapies to determine how and for whom their approvals may impact the team-based approach to AD management

Part 3: Evolving Roles in Alzheimer's Disease Management: Team-based Care in the Modern Age of Disease-Modifying Therapy

  • Outline optimal strategies for allocation of team resources, delineation of care roles, and communication between disciplines across the spectrum of AD management in order to maximize clinic flow and patient outcomes
Course summary
Course opens: 
Course expires: 

 James E. Galvin, MD, MPH (Moderator & Chair)
 Professor of Neurology
 Director, Comprehensive Program for Brain Health
 University of Miami Miller School of Medicine
 Miami, FL



 Charles P. Vega, MD
 Clinical Professor, Family Medicine
 Associate Dean, School of Medicine
 University of California, Irvine
 Orange, CA



 Timothy M. Shepherd, MD, PhD
 Associate Professor, Department of Radiology
 NYU Grossman School of Medicine
 New York, NY



 Malaz A. Boustani, MD, MPH
 Director, Senior Care Innovation Eskenazi Health
 Richard M. Fairbanks Professor of Aging Research
 Indiana University School of Medicine
 Indianapolis, IN

Credit for this program has expired. The accreditation information below is based on the activity release date.

This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.


Designation Statement


This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Efficient, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue will provide a maximum of 1.75 AMA PRA Category 1 Credits™ for participation in the enduring activity elements. Physicians will be invited to claim credit commensurate with the extent of their participation across the 3-part series.


Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Purdue will provide a maximum of 1.75 contact hours of nursing continuing professional development.

Physician Assistants

Purdue has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This serial activity will be designated for 1.75 AAPA Category 1 CME Credits. PAs should only claim credit commensurate with the extent of their participation.


Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution.
Purdue will award a maximum of 1.75 contact hours (0.175 CEUs) to pharmacists who participate in this knowledge-based activity series.

Conflicts of Interest Disclosure Policy:

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

All relevant conflicts of interest have been mitigated prior to the start of the activity.

None of the planners, reviewers, Efficient, LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Accredited Provider Disclosures

Faculty Disclosures

Dr. Galvin:
Speakers’ Bureau: Alpha Cognition, Biogen, Cognivue, Eisai, Genentech, Roche
Dr. Vega:
Consulting Fees: GlaxoSmithKline, Johnson and Johnson
Dr. Shepherd:
Dr. Shepherd has no relevant financial information to disclose.
Dr. Boustani:
Ownership Interest/Shareholder: Blue Agilis, Inc, DigiCare Realized, PPHM, LLC, RestUP, LLC
Speakers’ Bureau: Acadia, Biogen, Eisai, Genentech, Lilly, Merck
Grants/Research Support: Merck
Consulting Fees: Eisai, Genentech

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Supporter

This activity is supported by an educational grant from Genentech, a member of the Roche group.
Please login or register to take this course.
Please login or register to take this course.
Please login or register to take this course.


Please login or register to take this course.